title: A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer.
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Geynisman
authors.forename: Russell Z
authors.initials: RZ
authors.lastname: Szmulewitz
authors.forename: Walter M
authors.initials: WM
authors.lastname: Stadler
mesh_terms: D006801:Humans; D008297:Male; D000329:Advertising; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D002369:Castration; D004311:Double-Blind Method; D057239:Early Termination of Clinical Trials; D007722:Health Knowledge, Attitudes, Practice; D007610:Kallikreins / Q000097:blood; D010353:Patient Education as Topic; D018579:Patient Selection; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D012107:Research Design; D013739:Testosterone / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015337:Multicenter Studies as Topic; D017322:Clinical Trials, Phase II as Topic
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007610:Kallikreins; C549870:KLK3 protein, human; D017430:Prostate-Specific Antigen; D013739:Testosterone